A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact
In a Perspective accompanying Hill and colleagues, Elliot Marseille and James Kahn compare the history of pricing and availability of ART for HIV with that of the new HCV drugs and discuss strategies for providing treatment in LMIC even in the face of high costs.
Vyšlo v časopise:
A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact. PLoS Med 13(5): e32767. doi:10.1371/journal.pmed.1002031
Kategorie:
Perspective
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1002031
Souhrn
In a Perspective accompanying Hill and colleagues, Elliot Marseille and James Kahn compare the history of pricing and availability of ART for HIV with that of the new HCV drugs and discuss strategies for providing treatment in LMIC even in the face of high costs.
Zdroje
1. Johnson C, Dennis B. How an $84,000 drug got its price: ‘Let’s hold our position … whatever the headlines.’ Washington Post. December 1, 2015 [cited 2016 April 12]. https://www.washingtonpost.com/news/wonk/wp/2015/12/01/how-an-84000-drug-got-its-price-lets-hold-our-position-whatever-the-headlines/.
2. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355. doi: 10.1371/journal.pone.0081355 24367482; PMCID: PMC3867319.
3. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Int Med. 2011;155(4):209–16. doi: 10.7326/0003-4819-155-4-201108160-00358 21768555.
4. McNeil DG Jr. Companies to cut cost of AIDS drugs for poor nations. NY Times (Print). 2000:A1,4. 11873792.
5. Medecins Sans Frontieres. Untangling the Web of Antiretrovial Price Reductions: a pricing guide for the purchase of ARVs for developing countries, 17th Edition. Geneva: July 2014.
6. U.S. Food and Drug Administration. FDA approves first combination pill to treat hepatitis C 2014 [updated October 10, 2014]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm.
7. Chaudhry A. Pakistani firm authorised to manufacture hepatitis C oral drug: Dawn; October 6, 2015 [cited 2016]. http://www.dawn.com/news/1211111.
8. Chen C. His Job Is to Sell a $1,000 Pill for $10 Without Losing Money: Bloomberg; February 29, 2016 [cited 2016 April 8]. http://www.bloomberg.com/news/articles/2016-02-29/his-job-is-to-sell-a-1-000-pill-for-10-without-losing-money.
9. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, et al. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med. 2016;176(1):65–73. doi: 10.1001/jamainternmed.2015.6011 26595724.
10. European Association for the Study of the Liver. Scientists find a way to cure hepatitis C with 6 weeks of treatment. 2016. https://www.sciencedaily.com/releases/2016/04/160416090015.htm
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2016 Číslo 5
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Estimating the Risk of Chronic Pain: Development and Validation of a Prognostic Model (PICKUP) for Patients with Acute Low Back Pain
- Prioritizing Surgical Care on National Health Agendas: A Qualitative Case Study of Papua New Guinea, Uganda, and Sierra Leone
- A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact
- Toward a Common Secure Future: Four Global Commissions in the Wake of Ebola